The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Soleno Therapeutics, Inc. (“Soleno” or “the Company”) (NASDAQ: SLNO) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Soleno is the subject of a report published by Seeking Alpha on September 10, 2025, titled: “Soleno drops on death of patient treated with Vykat XR.” The article explains, “According to the FDA’s Adverse Event Reporting database, the patient died in August due to pulmonary embolism after undergoing treatment with Vykat XR.” Based on this news, shares of Soleno fell by more than 14.7% in afternoon trading on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250910169010/en/